ClinicalRM will provide regulatory support personnel and may also provide equipment, supplies, facilities, transportations, tools and materials necessary to support USAMMDA's mission. The contract is effective for 5 years, including option renewals, as of November 1, 2012.
USAMMDA supports ongoing efforts to develop new drugs, vaccines, devices and medical support equipment that enhance readiness, endures the provision of the highest quality medical care to the Department of Defense, and maximizes the survival of medical casualties on the battlefield.
"ClinicalRM is honored to continue the support of the important USAMMDA mission through this new contract," said Edie Druktenis, program manager, ClinicalRM. "Our staff is highly qualified and have proven to be a great asset to the mission over the last couple of years to move solutions forward, developing medical material to protect and sustain the warfighter.”